UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the Securities Exchange Act of 1934
June
16, 2014
Date
of Report (Date of earliest event reported)
AGENUS INC.
(Exact
name of registrant as specified in its charter)
DELAWARE
|
000-29089
|
06-1562417
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
3 Forbes Road
Lexington, MA
|
02421
|
(Address
of principal executive offices)
|
(Zip
Code)
|
781-674-4400
(Registrant’s
telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions (see General Instruction A.2. below):
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 7.01 Regulation FD Disclosure
On June 16, 2014, the Company announced that its common stock will be
included in the broad-market Russell 3000® Index and
Russell Global Index when Russell Investments reconstitutes its
comprehensive set of U.S. and global equity indexes on June 27, 2014,
according to a preliminary list of additions on www.russell.com/indexes.
The full text of the press release issued in connection with the
announcement is being furnished as Exhibit 99.1 to this current report
on Form 8-K.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibit is filed herewith:
99.1 Press Release dated June 16, 2014
SIGNATURES
Pursuant to
the requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
AGENUS INC.
|
|
|
Date: June 16, 2014
|
By:
|
/s/ Christine M. Klaskin
|
|
|
|
Christine M. Klaskin
|
|
VP, Finance
|
EXHIBIT INDEX
Exhibit No.
|
|
Description of Exhibit
|
|
|
|
99.1
|
|
Press Release dated June 16, 2014
|
Exhibit 99.1
Agenus
Selected for Inclusion in the Russell 3000 Index and Global Index
LEXINGTON, Mass.--(BUSINESS WIRE)--June 16, 2014--Agenus, Inc.
(NASDAQ:AGEN), an immuno-oncology company developing a portfolio of
checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants,
announced that it has been selected for inclusion in the broad-market
Russell 3000 Index and Russell Global Index when Russell
Investments reconstitutes its comprehensive set of U.S. and global
equity indexes on June 27, 2014, according to a preliminary list of
additions on www.russell.com/indexes.
Annual reconstitution of Russell’s U.S. indexes captures the 4,000
largest U.S. stocks as of the end of May, ranking them by total market
capitalization. Membership in the Russell 3000, which remains in place
for one year, means automatic inclusion in the large-cap Russell 1000
Index or small-cap Russell 2000 Index as well as the appropriate growth
and value style indexes. Russell determines membership for its equity
indexes primarily by objective, market-capitalization rankings and style
attributes.
"We are very pleased to be included in the 2014 reconstitution of the
Russell Indexes,” said Garo H. Armen, Ph.D., chairman and CEO of Agenus.
“We expect our new presence in these indexes will expose Agenus to a
wider range of institutions and investors, allowing us to broaden our
shareholder base."
The Russell 3000 also serves as the U.S. component to the Russell Global
Index, which Russell launched in 2007.
Russell indexes are widely used by investment managers and institutional
investors for index funds and as benchmarks for active investment
strategies. Approximately $5.2 trillion in assets are benchmarked to the
Russell Indexes. Russell calculates more than 700,000 benchmarks daily
covering approximately 98 percent of the investable market globally,
more than 80 countries and 10,000 securities. These investment tools
originated from Russell’s multi-manager investment business in the early
1980s when the company saw the need for a more objective, market-driven
set of benchmarks in order to evaluate outside investment managers.
Total returns data for the Russell 3000 and other Russell Indexes is
available at http://www.russell.com.
About Russell
Russell Investments (Russell) is a global asset manager and one of only
a few firms that offers actively managed multi-asset portfolios and
services that include advice, investments and implementation. Russell
stands with institutional investors, financial advisors and individuals
working with their advisors—using the firm’s core capabilities that
extend across capital market insights, manager research, portfolio
construction, portfolio implementation and indexes to help each achieve
their desired investment outcomes.
Russell has more than $259 billion in assets under management (as of
3/31/2014) and works with over 2,500 institutional clients, independent
distribution partners and individual investors globally. As a consultant
to some of the largest pools of capital in the world, Russell has $2.4
trillion in assets under advisement (as of 6/30/2013). It has four
decades of experience researching and selecting investment managers and
meets annually with more than 2,200 managers around the world. Russell
traded more than $1.6 trillion in 2013 through its implementation
services business. Russell also calculates approximately 700,000
benchmarks daily covering 98% of the investable market globally,
including more than 80 countries and more than 10,000 securities.
Approximately $5.2 trillion in assets are benchmarked (as of 12/31/2013)
to the Russell Indexes, which have provided investors with 30 years of
smarter beta.
About Agenus
Agenus is an immuno-oncology company developing a portfolio of
checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants.
Agenus’ checkpoint modulator programs target GITR, OX40, CTLA-4, LAG-3,
TIM-3 and PD-1. The company’s proprietary discovery engine Retrocyte
Display® is used to generate fully human therapeutic
antibody drug candidates. The Retrocyte Display platform uses a
high-throughput approach incorporating IgG format human antibody
libraries expressed in mammalian B-lineage cells. Agenus’ heat shock
protein vaccines for cancer and infectious disease are in Phase 2
studies. The company’s QS-21 Stimulon® adjuvant
platform is extensively partnered with GlaxoSmithKline and Janssen and
includes several candidates in Phase 3 trials. For more information,
please visit www.agenusbio.com, or connect with the company on
Facebook, LinkedIn, Twitter and Google+. For more information, please
visit www.agenusbio.com.
Forward-Looking Statement
This press release contains forward-looking statements, including
statements regarding the Company’s anticipated inclusion in Russell
Indexes and the impact this could have on our shareholder base. These
forward-looking statements are subject to risks and uncertainties that
could cause actual results to differ materially. These risks and
uncertainties include, among others, the factors described under the
Risk Factors section of our Annual Report on Form 10-Q filed with the
Securities and Exchange Commission for the year ended March 31, 2014.
Agenus cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These statements
speak only as of the date of this document, and Agenus undertakes no
obligation to update or revise the statements. All forward-looking
statements are expressly qualified in their entirety by this cautionary
statement. Agenus’ business is subject to substantial risks and
uncertainties, including those identified above. When evaluating Agenus’
business and securities, investors should give careful consideration to
these risks and uncertainties.
CONTACT:
Media and Investors:
Jonae R. Barnes, 617-818-2985
Vice
President Investor Relations and Corporate Communications
jonae.barnes@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024